Regulatory Agency's Tentative Approval Decision

The U.S. Food and Drug Administration (FDA) has granted tentative approval for Dr. Reddy's Laboratories Ltd. (ticker: RDY)'s application for Sitagliptin Phosphate tablets, a generic version of the type 2 diabetes drug Januvia. This approval (ANDA 214700) is granted because the drug meets the standards for efficacy and safety, but its final market launch is pending due to the existing patent or exclusivity rights of the original drug. With the patent for Merck's Januvia expiring in the U.S. market around May 2026, this tentative approval signifies that Dr. Reddy's has proactively secured the necessary regulatory requirements to enter the market immediately upon patent expiration. This is a crucial regulatory milestone for generic drug developers to establish the fastest possible launch schedule in anticipation of the patent cliff.

Mechanism of Action and Market Value of Sitagliptin

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of drugs used to treat diabetes. It works by promoting the secretion of incretin hormones, which stimulate insulin release and lower glucagon levels, thereby regulating blood sugar. For a long time, it has been a core component of the standard of care for diabetes due to its excellent tolerability and low risk of hypoglycemia. Although it now faces fierce competition from GLP-1 receptor agonists and SGLT-2 inhibitors, which boast cardiovascular benefits and weight loss effects, it still maintains a significant market size. The entry of affordable, high-quality generics into the market is expected to alleviate the financial burden of healthcare costs and significantly improve access to medication for patients with type 2 diabetes.

Declining Sales of the Original Brand

The original product, Merck's Januvia and Janumet franchise, was once a blockbuster drug with annual sales exceeding $6 billion. However, as the patent expiration date approaches, sales of the original product have been declining rapidly, from $3.4 billion in 2023 to $2.3 billion in 2024. This is a result of patent expirations and price reduction pressures that have already begun in the U.S. and other major markets worldwide, as well as competition from biosimilars and generics. In particular, the U.S. government's inclusion of Januvia as a drug subject to Medicare price negotiations under the Inflation Reduction Act (IRA) has made further price reductions and sales declines inevitable.

Market Penetration Strategies of Latecomers

In this rapidly changing market, Dr. Reddy's acquisition of generic approval represents a significant opportunity to strengthen its U.S. generic portfolio and diversify its long-term revenue streams. The U.S. DPP-4 inhibitor market has a robust size of over $10 billion annually, and as the generic penetration rate increases, the contribution to sales will be even greater. Dr. Reddy's plans to increase its market share by leveraging its low manufacturing costs in India and its global supply chain. This is a good example of how a late-stage pharmaceutical company quickly obtains regulatory approval in anticipation of the patent expiration of the original company and implements a market entry strategy.